Weekly cisplatin given for 2 months versus cisplatin plus cyclophosphamide given for 5 months after cytoreductive surgery for advanced ovarian cancer

Journal of Clinical Oncology

Volumn 15, Issue 5, 1997, Pages 1938-1944

  Bolis, G ^a   Favalli, G ^a   Danese, S ^a   Zanaboni, F ^a   Mangili, G ^a   Scarabelli, C ^a   Tateo, S ^a   Valsecchi, M G ^a   Scarfone, G ^a   Richiardi, G ^a   Frigerio, L ^a   Melpignano, M ^a   Villa, A ^a   Parazzini, F ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; METOCLOPRAMIDE; SEROTONIN ANTAGONIST;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OVARY CANCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0030986626     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.5.1938     Document Type: Article

References (19)

1. Ozols RF, Young RC: Chemotherapy of ovarian cancer. Semin Oncol 18:222-232, 1991
2. NIH Consensus Development Panel on Ovarian Cancer: Ovarian Cancer. Screening, treatment, and follow-up. JAMA 273:491-497, 1995
3. Advanced Ovarian Cancer Trialists Group: Chemotherapy in advanced ovarian cancer: An overview of randomised clinical trials. Br Med J 303:884-893, 1991
4. Levin L, Hryniuk WM: Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J Clin Oncol 5:756-767, 1987
5. Ngan HYS, Choo YC, Cheung M, et al: A randomized study of high-dose versus low-dose cis-platinum combined with cyclophosphamide in the treatment of advanced ovarian cancer. Chemotherapy 35:221-227, 1989
6. Kaye SB, Paul J, Cassidy J, et al: Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. J Clin Oncol 14:2113-2119, 1996
7. Green JA, Dawson AA, Fell LE: Measurement of drug dosage intensity in MVPP therapy in Hodgkin's disease. Br J Clin Pharmacol 9:511-514, 1980
8. Henderson IC, Hayes DF, Gelman R: Dose response in the treatment of breast cancer: A critical review. J Clin Oncol 6:1501-1515, 1988
9. Torri V, Korn EL, Simon R: Dose intensity analysis in advanced ovarian cancer patients. Br J Cancer 67:190-197, 1993
10. Bolis G, Favalli G, Giardina G, et al: A multicenter randomized trial comparing weekly platinum (PW) vs cyclophosphamide plus platinum (CP) in advanced ovarian cancer (AOC). Proc Am Soc Clin Oncol 13:259, 1994 (abstr)
11. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
12. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
13. Peto R, Pike MC, Armitage P, et al: Design and analysis of randomised clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 35:1-39, 1977
14. Cox DR: Regression models and life-tables. J Roy Stat Soc (B) 34:187-220, 1972
15. Freedman LS: Tables of the number of patients required in clinical trials using the logrank test. Stat Med 1:121-129, 1982
16. Repetto L, Pace M, Mammoliti S, et al: The impact of received dose intensity on the outcome of advanced ovarian cancer. Eur J Cancer 29:181-184, 1993
17. McGuire WP, Hoskins WJ, Brady MF, et al: Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 13:1589-1599, 1995
18. Colombo N, Pittelli MR, Parma G, et al: Cisplatin (P) dose intensity in advanced ovarian cancer (AOC): A randomized study of conventional dose (DC) vs dose-intense (DI) cisplatin monochemotherapy. Proc Am Soc Clin Oncol 12:255, 1993 (abstr)
19. Gore ME, Malnwaring PN, Macfarlane V, et al: A randomized study of high versus standard dose carboplatin in patients (PTS) with advanced epithelial ovarian cancer (EOC). Proc Am Soc Clin Oncol 15:284, 1996 (abstr)